Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort

Abstract Objectives to evaluate over a 48-month follow-up period the: 1) long-term effectiveness and safety; 2) drug retention rate (DRR); 3) impact of comorbidities and bDMARDs line on MDA and DAPSA remission/low disease activity (LDA) of secukinumab in a multicenter Italian cohort of PsA patients....

詳細記述

書誌詳細

出版年:	Arthritis Research & Therapy
主要な著者:	Roberta Ramonda, Mariagrazia Lorenzin, Maria Sole Chimenti, Fabiola Atzeni, Angelo Semeraro, Salvatore D’Angelo, Carlo Selmi, Augusta Ortolan, Antonio Marchesoni, Maria Manara, Michele Maria Luchetti Gentiloni, Leonardo Santo, Carlo Salvarani, Alberto Cauli, Maurizio Rossini, Giorgio Amato, Giacomo Cozzi, Laura Scagnellato, Mario Ferraioli, Antonio Carriero, Elena Fracassi, Francesco Giorgio, Andrea Doria, Rosario Foti, Antonio Carletto, on behalf Spondyloarthritis and Psoriatic Arthritis SIR Study Group “Antonio Spadaro”
フォーマット:	論文
言語:	英語
出版事項:	BMC 2024-09-01
主題:	Psoriatic arthritis Biologics Secukinumab Remission/Effectiveness Safety Drug retention rate
オンライン･アクセス:	https://doi.org/10.1186/s13075-024-03401-x